A Novel Synthesized Tyrosinase Inhibitor: (E)-2-((2,4-Dihydroxyphenyl)diazenyl)phenyl 4-Methylbenzenesulfonate as an Azo-Resveratrol Analog
摘要:
We synthesized a novel series of (E)-2-((substituted phenyl)diazenyl)phenyl 4-methylbenzenesulfonate derivatives (2 and 3) and (E)-2-((substituted phenyl)diazenyl)phenol derivatives (4 and 5), and conducted an evaluation in order to determine their inhibitory effects on mushroom tyrosinase, with the aim of discovering a tyrosinase inhibitor. Most of the compounds (3-5) exhibited higher inhibitory effects than kojic acid (IC50 = 49.08 mu m), a representative tyrosinase inhibitor. A novel synthesized compound, (E)-2-((2,4-dihydroxyphenyl)diazenyl)phenyl 4-methylbenzenesulfonate (3), showed the best results with an IC50 of 17.85 mu m, and showed competitive inhibition on Lineweaver-Burk plots, as further confirmed by the docking results. In addition, active compounds 3-5 were not cytotoxic to cultured B16F10 cells at the concentrations tested, and inhibited both tyrosinase and melanin synthesis. Therefore the active compounds (3-5) might be considered excellent candidates for use in the development of therapeutic agents for diseases associated with hyper-pigmentation.
Nitric oxide donating derivatives for the treatment of cardiovascular disorders
申请人:Tucker Joseph
公开号:US20050080024A1
公开(公告)日:2005-04-14
Compounds comprising nitric oxide derivatives of stilbenes, polyphenols and flavonoids and methods of their use are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.
Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders
申请人:Tucker Joseph
公开号:US20050080021A1
公开(公告)日:2005-04-14
Compounds and methods are provided for treating patients suffering from any of hypercholesterolemia, vascular oxidative stress and endothelial dysfunction.
A process for producing polyphenylene oxide which comprises contacting a phenolic monomer with oxygen in the presence of a catalyst composed of a manganese (II) salt and an ortho-hydroxyazo compound represented by the following formula:
where A and B represent identical or different arylene ring having a valency of at least 2 and having an oxy group and an azo group directly linked to the ortho carbon atoms of the arylene ring and R represents hydrogen or lower alkyl group, or in the presence of said catalyst and an amine, in a polymerization solvent containing a base and thereby subjecting said phenolic monomer to an oxidative polymerization.
一种生产聚苯醚的工艺,它包括在由锰(II)盐和下式代表的邻羟基偶氮化合物组成的催化剂存在下,使酚类单体与氧气接触:
式中 A 和 B 代表相同或不同的芳烯环,其价数至少为 2,并有一个氧基和一个偶氮基直接连接到芳烯环的正碳原子上,R 代表氢或低级烷基,或在所述催化剂和胺的存在下,在含有碱的聚合溶剂中,使所述酚类单体进行氧化聚合。
TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT
申请人:RESVERLOGIX CORP.
公开号:EP1670485A1
公开(公告)日:2006-06-21
NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS